Den progressionsfri overlevelse efter 6 måneder i intent- to- treat- populationen var 80% (XELIRI plus bevacizumab) versus 74% (XELOX plus bevacizumab).
43 (XELIRI plus bevacizumab) versus 74% (XELOX plus bevacizumab).